Ubs Group Ag Annexon, Inc. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANNX
# of Institutions
156Shares Held
101MCall Options Held
3.73MPut Options Held
1.3M-
Bain Capital Life Sciences Investors, LLC Boston, MA8.45MShares$59.4 Million8.47% of portfolio
-
Satter Management Co., L.P.7.41MShares$52.1 Million71.21% of portfolio
-
Bvf Inc San Francisco, CA7MShares$49.2 Million1.05% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$46.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.43MShares$45.2 Million2.05% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $335M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...